Treatment and prevention of Yersinia enterocolitica and Yersinia pseudotuberculosis infection
- Robert V Tauxe, MD, MPH
Robert V Tauxe, MD, MPH
- Division of Bacterial and Mycotic Diseases
- Centers for Disease Control and Prevention
- Section Editors
- Stephen B Calderwood, MD
Stephen B Calderwood, MD
- Editor-in-Chief — Infectious Diseases
- Section Editor — Bacterial Infections
- Professor of Medicine (Microbiology and Immunobiology)
- Harvard Medical School
- Sheldon L Kaplan, MD
Sheldon L Kaplan, MD
- Editor-in-Chief — Pediatrics
- Section Editor — Pediatric Infectious Diseases
- Professor and Vice Chairman for Clinical Affairs
- Baylor College of Medicine
Yersinia species are gram-negative coccobacilli, which are facultative anaerobes . Three species of Yersinia produce human illness: Yersinia pestis (the causative agent of human plague), Yersinia enterocolitica (the causative agent of yersiniosis), and Yersinia pseudotuberculosis. Y. enterocolitica and Y. pseudotuberculosis most commonly cause enterocolitis; Y. enterocolitica is the more common of the two species to cause disease.
The treatment of Y. enterocolitica and Y. pseudotuberculosis infection will be reviewed here. The epidemiology, microbiology, pathogenesis, clinical manifestations, and diagnosis of these infections and issues related to plague are discussed separately. (See "Epidemiology of yersiniosis" and "Microbiology and pathogenesis of Yersinia infections" and "Clinical manifestations and diagnosis of Yersinia infections" and "Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)" and "Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)".)
Optimal treatment strategies for Yersinia spp infections are unclear. Although treatment appears not to impact mild intestinal disease, fecal shedding decreases following antimicrobial treatment . This by itself does not justify treatment, as person-to-person transmission is rare. However, antimicrobial treatment may be lifesaving in invasive infections.
There has been one controlled trial of antimicrobial therapy for Y. enterocolitica infection and one for Y. pseudotuberculosis gastroenteritis [3,4]. Neither demonstrated a clinical benefit from treatment, though, in both treated groups, the pathogen was rapidly cleared from feces. In addition to these studies, treatment recommendations are based on susceptibility data and clinical case series.
In vitro studies — Yersinia susceptibilities vary with the serotype, and therapeutic decisions should be guided by the susceptibility pattern of the clinical isolate . The Y. enterocolitica serotype most commonly associated with illness (O:3) usually produces chromosomally-mediated beta-lactamases and thus is resistant to penicillin, ampicillin, and most first generation cephalosporins [1,5]. Yersinia is also usually resistant to macrolides.
Subscribers log in hereLiterature review current through: Jul 2017. | This topic last updated: Apr 18, 2017.References
- Bottone EJ. Yersinia enterocolitica: the charisma continues. Clin Microbiol Rev 1997; 10:257.
- Ostroff SM, Kapperud G, Lassen J, et al. Clinical features of sporadic Yersinia enterocolitica infections in Norway. J Infect Dis 1992; 166:812.
- Pai CH, Gillis F, Tuomanen E, Marks MI. Placebo-controlled double-blind evaluation of trimethoprim-sulfamethoxazole treatment of Yersinia enterocolitica gastroenteritis. J Pediatr 1984; 104:308.
- Sato K, Ouchi K, Komazawa M. Ampicillin vs. placebo for Yersinia pseudotuberculosis infection in children. Pediatr Infect Dis J 1988; 7:686.
- Pham JN, Bell SM, Hardy MJ, et al. Comparison of beta-lactamase production by Yersinia enterocolitica biotype 4, serotype O:3 isolated in eleven countries. Contrib Microbiol Immunol 1995; 13:180.
- Preston M, Brown S, Borczyk A, et al. Antimicrobial susceptibility of pathogenic Yersinia enterocolitica isolated in Canada from 1972 to 1990. Contrib Microbiol Immunol 1995; 13:175.
- Stolk-Engelaar V, Meis J, Mulder J, et al. Activity of 24 antimicrobials against Yersinia enterocolitica. Contrib Microbiol Immunol 1995; 13:172.
- Capilla S, Ruiz J, Goñi P, et al. Characterization of the molecular mechanisms of quinolone resistance in Yersinia enterocolitica O:3 clinical isolates. J Antimicrob Chemother 2004; 53:1068.
- Capilla S, Goñi P, Rubio MC, et al. Epidemiological study of resistance to nalidixic acid and other antibiotics in clinical Yersinia enterocolitica O:3 isolates. J Clin Microbiol 2003; 41:4876.
- Frydén A, Bengtsson A, Foberg U, et al. Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study. BMJ 1990; 301:1299.
- Press N, Fyfe M, Bowie W, Kelly M. Clinical and microbiological follow-up of an outbreak of Yersinia pseudotuberculosis serotype Ib. Scand J Infect Dis 2001; 33:523.
- Cover TL, Aber RC. Yersinia enterocolitica. N Engl J Med 1989; 321:16.
- Jensen KT, Arpi M, Frederiksen W. Yersinia enterocolitica septicemia in Denmark 1972-1991: a report of 100 cases. Contrib Microbiol Immunol 1995; 13:11.
- Gayraud M, Scavizzi MR, Mollaret HH, et al. Antibiotic treatment of Yersinia enterocolitica septicemia: a retrospective review of 43 cases. Clin Infect Dis 1993; 17:405.
- Black RE, Slome S. Yersinia enterocolitica. Infect Dis Clin North Am 1988; 2:625.
- Rosner BM, Stark K, Höhle M, Werber D. Risk factors for sporadic Yersinia enterocolitica infections, Germany 2009-2010. Epidemiol Infect 2012; 140:1738.
- Rimhanen-Finne R, Niskanen T, Hallanvuo S, et al. Yersinia pseudotuberculosis causing a large outbreak associated with carrots in Finland, 2006. Epidemiol Infect 2009; 137:342.
- Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001; 41:1493.